| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Maternal Serum AFP (MASAFP)
Test CodeLAB692
Quest Code
5059
CPT Codes
82105
Includes
AFP, Maternal Risk Interpretation
Preferred Specimen
1 mL serum in gold top tube
Minimum Volume
0.5 mL
Other Acceptable Specimens
Plain red top tube
Instructions
For manual orders use “Maternal Serum Screen Requisition"
The maternal serum AFP test in pregnant women should be performed between 15.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial MSAFP results are abnormal. Specimens submitted before 15.0 weeks or after 22.9 weeks gestation cannot be properly evaluated.
The Maternal Serum Screen Requisition designed to obtain patient data and the patient's informed consent must be utilized when ordering the maternal serum AFP test. Because the maternal serum AFP test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: Date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient diabetic status (is patient insulin dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
The maternal serum AFP test in pregnant women should be performed between 15.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial MSAFP results are abnormal. Specimens submitted before 15.0 weeks or after 22.9 weeks gestation cannot be properly evaluated.
The Maternal Serum Screen Requisition designed to obtain patient data and the patient's informed consent must be utilized when ordering the maternal serum AFP test. Because the maternal serum AFP test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: Date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient diabetic status (is patient insulin dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
Transport Container
Serum separator tube (SST)
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 45 days
Refrigerated: 14 days
Frozen: 45 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly lipemic
Methodology
Immunoassay (IA)
FDA Status
This test code is for non-New York patient testing. For New York patient testing, use test code 92788.
Setup Schedule
8 AM Mon-fri
Report Available
4 days
Limitations
MSAFP results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. MSAFP does not screen for chromosomal abnormalities.
Clinical Significance
Maternal serum alpha-fetoprotein (MSAFP) is used for prenatal screening. Maternal serum Alpha-Fetoprotein (AFP) elevation is associated with open neural tube defects, multiple gestation, placental anomalies, ventral abdominal wall defects, congenital nephrosis, and oligohydramnios. Follow-up for abnormal AFP results include genetic counseling, level II or III ultrasound examination and consideration of amniocentesis for chromosome and AFP analysis. MSAFP is not to be used as a screening test for chromosomal abnormalities.
Performing Laboratory
| Quest Diagnostics - South Region |
